---

BDP China 2020 Joint Opening Plenary Sessions

---

Opening Address:
China’s Big Leap towards BioPharma 2030:
Innovation, Industrialisation, Internationalisation

Dr. Song Rulin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

 KEYNOTE ADDRESS
China’s Biologics Facilities for the Future – WuXi’s Story on Technology and Innovation

Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

Manufacturers’ Panel:
New Therapies, New Tech and New Investment

Panelists:
Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China
Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China

End of Morning Plenary Sessions

Morning Networking & Refreshment Break

---

2^nd Cell and Gene Therapies Manufacturing Resumes

 China Market

---

Industry Panel:
Regulatory Pathways for Cell and Gene Therapies in the Region, and China 

Finding the Market Growth

Addressing the Next Wave of Innovations in Cell Therapies

Networking Lunch

---

Accelerating Manufacturing

---

China’s CAR-T Manufacturing Scenarios:
Facilities Design and Construction Call Therapies

Manufacturers’ Panel:
Manufacturing Challenges and Opportunities for Autologous T Cells

• Industrialisation in China – Collaboration for global standards and developing cGMP manufacturing facilities

Afternoon Networking & Refreshment Break

---

Commercialisation Strategies

---

Biotech Investors Roundtable: Financial Incentives, Investments and Pricing 

Commercialisation Models and Case studies of CAR-Ts

Japan, Korea and Taiwan Case Studies

Close of Day 1

 

*Please note that conference agenda and timing are subjected to change according to market development.

---

BDP China 2020 Joint Opening Plenary Sessions

---

Keynote Address:
China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Fu Wei, Chief Executive Officer, CBC Group, China

Venture Capitals Roundtable: Show Me the Drug

Panelists:
Rani Jarkas, Chairman, Cedrus Investments, Hong Kong
Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China
Dr. John Zhu, Partner, 6 Dimensions Capital, China

End of Morning Plenary Sessions

Morning Networking & Refreshment Break

---

2^nd Cell and Gene Therapies Manufacturing Resumes

Technology and Innovation

---

Latest CGT Technology and Innovation Developments

 Innovations – CGT to Immuno-oncology

 Innovations in Precision Manufacturing and Tailored Therapies

Networking Lunch

---

Access and Pricing

---

 Payment Systems, Patient Access and Reimbursement Challenges in China  

 Product Registrations, Submission and Approvals 

 Case Studies – China, Japan, Korea, Taiwan

---

 Clinical Trials

---

Leaders’ Dialogue on Running a Successful CAR T Trial in China 

 Clinical Drug Development for Cell and Gene Therapies – How Ready Institutions Are?  

 Efficacy Evidence and Clinical Trials – How They Affect Product Launch and Outcomes-Based Pricing Arrangements

Afternoon tea break

---

Logistics and Supply Chain

---

Track, Track and Overall Effective Supply Chain Systems   

Case Study of Manufacturing and Supply Chian Challenge 

Close of Day 2

 

*Please note that conference agenda and timing are subjected to change according to market development